AbbVie Inc. (NYSE:ABBV)

Pills

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

One thing investors look for in an aging bull market, especially one trading near all-time highs, is rising earnings. That is the only way to justify multiples that creep up ...
Read Full Story »
intelinside

Should Investors Buy These 4 ‘Bad News’ Stocks for Big Gains?

Often when a company presents bad news, it is for a real reason, and it may indeed be a harbinger of worse things to come. Sometimes, though, bad news is ...
Read Full Story »
Pills

The Next 3 Likely Biotech Buyout Candidates

One good way for a company to increase sales and move past simple organic growth is to make an acquisition, and that is just what AbbVie Inc. (NYSE: ABBV) did ...
Read Full Story »
462542665

Just How Expensive Is the Pharmacyclics Buyout?

Pharmacyclics Inc. (NASDAQ: PCYC) has seen its stock surge in the past week as rumors swirl about a potential acquisition. News finally broke late Wednesday that there was an official ...
Read Full Story »
pills

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

After the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings per share (EPS) and $26.31 billion in revenue. This is ...
Read Full Story »
Pfizer logo

Jefferies 4 Top Pharmaceutical Stocks to Buy

With the stock market hitting all-time highs, many investors are starting to wonder which sectors still hold value. Although seeming rich, the market continues climbing a wall of worry to ...
Read Full Story »
Pills

Neurocrine Biosciences Announces New Offering

Neurocrine Biosciences Inc. (NASDAQ: NBIX) has announced that it will have another public offering of its common stock. The total offering is expected to raise an aggregate of roughly $225 ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Apple, Deckers, Dish, Pfizer, Petrobras and More

Stocks were soft on Monday despite OPEC hinting at a faster oil demand recovery than expected. The rally from last week was on the heels of a bad January, and ...
Read Full Story »
Pills

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today. ...
Read Full Story »
biotech

What to Expect From Gilead Earnings

Tuesday after the markets close, Gilead Sciences Inc. (NASDAQ: GILD) will report its fourth-quarter financial results. Thomson Reuters has consensus estimates of $2.22 in earnings per share (EPS) and $6.72 ...
Read Full Story »
462542665

Are Humira Sales Enough to Lift AbbVie?

AbbVie Inc. (NYSE: ABBV) reported its fourth-quarter financial results Friday before the markets open. This drug manufacturing giant posted earnings per share (EPS) of $0.89 and $5.37 billion in revenue. ...
Read Full Story »
Money background. Close-up.

Gilead Continues to Recover from Express Scripts Loss

After the markets closed on Thursday, Gilead Sciences Inc. (NASDAQ: GILD) was picked up by Anthem Inc. (NYSE: ANTM) to provide its hepatitis C drug as the primary option for ...
Read Full Story »
thumbs up

Is Gilead Already Coming Back Into Favor?

Over the past year, Gilead Sciences Inc. (NASDAQ: GILD) has been a top dog with regards to hepatitis C treatments, pulling in over $6.2 billion in sales for these treatments ...
Read Full Story »
downgrade sign

Analysts Predict Big Value Trap for Gilead Investors

AbbVie Inc. (NYSE: ABBV) and Express Scripts Holding Co. (NASDAQ: ESRX) entered into an exclusive distribution agreement following the U.S. Food and Drug Administration’s (FDA) approval of AbbVie’s hepatitis C ...
Read Full Story »
Pills

What the AbbVie and Express Script Deal Means for Gilead

AbbVie Inc. (NYSE: ABBV) received U.S. Food and Drug Administration (FDA) approval for its hepatitis C drug last Friday, and the drug will directly compete with treatments from Gilead Sciences Inc. ...
Read Full Story »